RxDoctor Payments DataLook up a doctor →

Daniel Alvarez, DO

Cardiovascular Disease · Wichita, KSNPI 1588646236

Payments from drug & device makers

$16,445in general payments, 2019–2025

Across 768 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Medtronic$1K
  • AstraZeneca$1K
  • Novartis$1K
  • plus $7K from 40 others

What the payments were for

  • Travel & lodging$1,4699%
  • Food & beverage$14,85090%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,445 in reported general payments places this provider in the 85th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$362,580
Medicare patients
1,530
Services billed
5,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban308$310,864
EliquisApixaban320$291,741
EntrestoSacubitril/Valsartan227$239,522
BrilintaTicagrelor94$67,273
Repatha SureclickEvolocumab56$50,858
JardianceEmpagliflozin40$40,914
MounjaroTirzepatide15$18,907
Repatha SyringeEvolocumab30$18,007
VerquvoVericiguat13$17,827
FarxigaDapagliflozin Propanediol11$17,402
MultaqDronedarone Hcl15$14,807
Digoxin211$4,795
Metoprolol Succinate483$4,778
ClopidogrelClopidogrel Bisulfate602$4,594
Amlodipine Besylate693$3,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,469$310,864308 claims
PfizerEliquis$543$291,741320 claims
NovartisEntresto$1,088$239,522227 claims
AstraZenecaBrilinta, Farxiga$1,111$84,675105 claims
Boehringer IngelheimJardiance$270$40,91440 claims
Lilly USA, LLCMounjaro$17$18,90715 claims
MerckVerquvo$774$17,82713 claims
Sanofi-aventis U.S. LLCMultaq$298$14,80715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →